Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
03 2019
Historique:
received: 05 05 2018
revised: 23 05 2018
accepted: 26 05 2018
pubmed: 17 6 2018
medline: 3 7 2020
entrez: 17 6 2018
Statut: ppublish

Résumé

Although hepatitis B and C have been the main drivers of hepatocellular carcinoma (HCC), nonalcoholic steatohepatitis (NASH) has recently become an important cause of HCC. The aim of this study was to assess the causes of HCC among liver transplant (LT) candidates in the United States. The Scientific Registry of Transplant Recipients (2002-2016) was used to estimate the trends in prevalence of HCC in LT candidates with the most common types of chronic liver disease: alcoholic liver disease (ALD), chronic hepatitis B (CHB), chronic hepatitis C, and NASH. 158,347 adult LT candidates were included. Of these, 26,121 (16.5%) had HCC; this proportion increased from 6.4% (2002) to 23.0% (2016) (trend P < .0001). Over the study period, CHC remained the most common etiology for HCC (65%). The proportions of HCC accounted for by CHC and ALD remained stable (both trend P > .10), the proportion of CHB decreased 3.1-fold (P < .0001), while the proportion of NASH in HCC increased 7.7-fold (from 2.1% to 16.2%; P < .0001). Furthermore, since 2002, the prevalence of HCC in LT candidates with NASH increased 11.8-fold, while this rate increased 6.0-fold in CHB, 3.4-fold in ALD, and 2.3-fold in CHC (all P < .0001); the increasing trend in NASH was steeper than that for any other etiology (P < .0001 in a trend regression model). The proportion of LT candidates with HCC who ultimately received a transplant or died while waiting did not differ between etiologies (P > .05). Nonalcoholic steatohepatitis is the most rapidly growing cause of HCC among US patients listed for liver transplantation.

Sections du résumé

BACKGROUND & AIMS
Although hepatitis B and C have been the main drivers of hepatocellular carcinoma (HCC), nonalcoholic steatohepatitis (NASH) has recently become an important cause of HCC. The aim of this study was to assess the causes of HCC among liver transplant (LT) candidates in the United States.
METHODS
The Scientific Registry of Transplant Recipients (2002-2016) was used to estimate the trends in prevalence of HCC in LT candidates with the most common types of chronic liver disease: alcoholic liver disease (ALD), chronic hepatitis B (CHB), chronic hepatitis C, and NASH.
RESULTS
158,347 adult LT candidates were included. Of these, 26,121 (16.5%) had HCC; this proportion increased from 6.4% (2002) to 23.0% (2016) (trend P < .0001). Over the study period, CHC remained the most common etiology for HCC (65%). The proportions of HCC accounted for by CHC and ALD remained stable (both trend P > .10), the proportion of CHB decreased 3.1-fold (P < .0001), while the proportion of NASH in HCC increased 7.7-fold (from 2.1% to 16.2%; P < .0001). Furthermore, since 2002, the prevalence of HCC in LT candidates with NASH increased 11.8-fold, while this rate increased 6.0-fold in CHB, 3.4-fold in ALD, and 2.3-fold in CHC (all P < .0001); the increasing trend in NASH was steeper than that for any other etiology (P < .0001 in a trend regression model). The proportion of LT candidates with HCC who ultimately received a transplant or died while waiting did not differ between etiologies (P > .05).
CONCLUSIONS
Nonalcoholic steatohepatitis is the most rapidly growing cause of HCC among US patients listed for liver transplantation.

Identifiants

pubmed: 29908364
pii: S1542-3565(18)30611-6
doi: 10.1016/j.cgh.2018.05.057
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

748-755.e3

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

Zobair Younossi (Z)

Center for Liver Diseases, Department of Medicine, Inova Health System, Falls Church, Virginia; Division of Gastroenterology and Hepatology, Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia. Electronic address: zobair.younossi@inova.org.

Maria Stepanova (M)

Center for Outcomes Research in Liver Disease, Washington, District of Columbia.

Janus P Ong (JP)

Department of Medicine, University of Philippines, Manila, Philippines.

Ira M Jacobson (IM)

Division of Gastroenterology and Hepatology, New York University School of Medicine, New York, New York.

Elisabetta Bugianesi (E)

Division of Gastroenterology, Department of Medical Sciences, University of Torino, Torino, Italy.

Ajay Duseja (A)

Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Yuichiro Eguchi (Y)

Liver Center, Saga University Hospital, Saga, Japan.

Vincent W Wong (VW)

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

Francesco Negro (F)

Division of Gastroenterology and Hepatology, University of Geneva, Geneva, Switzerland.

Yusuf Yilmaz (Y)

Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkey.

Manuel Romero-Gomez (M)

Digestive Diseases Unit, Virgin del Rocio University Hospital, Sevilla, Spain.

Jacob George (J)

Sorr Liver Centre, The Westmead Institute of Medical Research, University of Sydney, Westmead Hospital, Sydney, Australia.

Aijaz Ahmed (A)

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.

Robert Wong (R)

Division of Gastroenterology and Hepatology, Alameda Health System, Oakland, California.

Issah Younossi (I)

Center for Outcomes Research in Liver Disease, Washington, District of Columbia.

Mariam Ziayee (M)

Center for Outcomes Research in Liver Disease, Washington, District of Columbia.

Arian Afendy (A)

Center for Outcomes Research in Liver Disease, Washington, District of Columbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH